Pages that link to "Q48196103"

The following pages link to Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats (Q48196103):

Displaying 26 items.

• The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat (Q28293887) (← links)
• Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease (Q28542729) (← links)
• Adenosine A(2A) Receptor Antagonists and Parkinson's Disease (Q29346492) (← links)
• Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. (Q35489240) (← links)
• Mechanisms of induction of adenosine receptor genes and its functional significance (Q35692398) (← links)
• A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease (Q36057652) (← links)
• Target identification for CNS diseases by transcriptional profiling. (Q37175279) (← links)
• Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. (Q37627259) (← links)
• Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. (Q37844573) (← links)
• Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor (Q37902895) (← links)
• Neurotoxin-based models of Parkinson's disease (Q37959729) (← links)
• Adenosine A2A antagonists in Parkinson's disease: what's next? (Q38010070) (← links)
• A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. (Q38169996) (← links)
• Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued (Q38200930) (← links)
• History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents (Q38395423) (← links)
• Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A2A antagonism (Q39432789) (← links)
• Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism. (Q41249072) (← links)
• CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats (Q42481890) (← links)
• Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches (Q47137101) (← links)
• Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia (Q48112379) (← links)
• A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo (Q49452726) (← links)
• The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat (Q56700734) (← links)
• PBF509, an Adenosine A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders (Q58587583) (← links)
• Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease. (Q64901815) (← links)
• Potent, Metabolically Stable 2-Alkyl-8-(2H-1,2,3-triazol-2-yl)-9H-adenines as Adenosine A2A Receptor Ligands (Q87262241) (← links)
• Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease (Q92583755) (← links)